Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers

First Posted Date
2019-01-11
Last Posted Date
2024-12-20
Lead Sponsor
Emory University
Target Recruit Count
60
Registration Number
NCT03800693
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

First Posted Date
2019-01-03
Last Posted Date
2021-03-23
Lead Sponsor
Mian XI
Target Recruit Count
216
Registration Number
NCT03791905
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

First Posted Date
2018-12-24
Last Posted Date
2024-12-18
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
34
Registration Number
NCT03785873
Locations
🇺🇸

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States

🇺🇸

University of Utah, Salt Lake City, Utah, United States

and more 2 locations

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

First Posted Date
2018-12-21
Last Posted Date
2023-12-19
Lead Sponsor
Ashwin Somasundaram
Target Recruit Count
18
Registration Number
NCT03783936
Locations
🇺🇸

University of Iowa Hospital and Clinics, Iowa City, Iowa, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 4 locations

FOLFIRINOX for 2nd-line Treatment of BTC

First Posted Date
2018-12-19
Last Posted Date
2021-02-04
Lead Sponsor
Dong-A University Hospital
Target Recruit Count
34
Registration Number
NCT03778593
Locations
🇰🇷

Dong-A University Hospital, Busan, Korea, Republic of

Folinic Acid in Autism

Phase 2
Completed
Conditions
Autism Spectrum Disorder
Interventions
Drug: folinic acid
First Posted Date
2018-12-11
Last Posted Date
2019-12-03
Lead Sponsor
University of California, San Francisco
Target Recruit Count
18
Registration Number
NCT03771560
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

First Posted Date
2018-12-05
Last Posted Date
2024-07-31
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
320
Registration Number
NCT03764553
Locations
🇳🇱

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands

🇳🇱

Zuyderland Medisch Centrum, Geleen, Netherlands

🇳🇱

Tergooi ziekenhuizen, Hilversum, Netherlands

and more 32 locations

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Phase 3
Completed
Conditions
Colo-rectal Cancer
Interventions
Drug: Arfolitixorin
Drug: Leucovorin
First Posted Date
2018-11-23
Last Posted Date
2023-10-26
Lead Sponsor
Isofol Medical AB
Target Recruit Count
490
Registration Number
NCT03750786
Locations
🇺🇸

840-01 - HOAG Memorial Hospital, Newport Beach, California, United States

🇨🇦

124-11 - CISSS de Chaudière-Appalaches, Lévis, Quebec, Canada

🇫🇷

250-05 - Clinique Sainte Anne, Strasbourg, France

and more 91 locations

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

First Posted Date
2018-11-23
Last Posted Date
2021-06-30
Lead Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Target Recruit Count
31
Registration Number
NCT03751176
Locations
🇪🇸

ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain

🇪🇸

Hospital de Granollers, Granollers, Barcelona, Spain

🇪🇸

Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain

and more 15 locations

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

First Posted Date
2018-11-09
Last Posted Date
2023-12-19
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
11
Registration Number
NCT03736720
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

Stony Brook Cancer Center, Stony Brook, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy